You can now read 5 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

Mass. Movers

Dyax revenue increases, loss narrows

Shares of Burlington biopharmaceutical company Dyax Corp. rose on fourth-quarter revenue that reached $16.9 million, compared to $16.0 million last year. The loss per share narrowed to 2 cents, beating estimates of a 4-cent loss. Officials reported sales of Kalbitor, Dyax’s lead product, which treats hereditary angioedema, increased to $12.6 million, compared to $11.8 million last year. Hereditary angioedema is a rare problem with the immune system that causes swelling, particularly of the face and airways, and cramping.

Loading comments...
Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
Please enter a valid email will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of